Carter's, Inc.

▲ Bull Case

• ◆Tariff normalization to <20% (base) or 12–15% (bull) recovers gross margins from 43–44% trough to 47–49% by FY2027–28, yielding $1.40–2.00 of incremental adj. EPS ($18–26/share valuation upside to $65–85).
• ◆$45M restructuring savings plus comp recovery creates EPS leverage: 150-store closure removes $110M underperforming revenue; full lease/headcount savings arrive by FY2028. Base case projects $6.80 FY2028 adj. EPS; at 12x = $81.60/share.
• ◆Sharon Price John's Build-A-Bear turnaround credentials enable CEO-quality P/E re-rating: from 11.9x (governance-discount trough) to 13.5x on same earnings base = +13% stock upside, historical precedent for 15–20% re-rating post-leadership stabilization.

▼ Bear Case

• ◆Vietnam tariff escalation to 46%+ without extension creates $100–150M annual COGS headwind, compressing adj. EPS to $1.50–2.00, eliminating restructuring savings value, testing dividend coverage. At 9–10x P/E on $2.00 EPS = $18–20/share (50% decline).
• ◆Structural demand impairment—secular birth-rate decline (-1%/year TAM compression), OshKosh brand deterioration ($30M impairment, 2–12 relevance declining), irreversible retail channel shift—suggests $2.8–2.9B revenue ceiling vs. $3.1–3.2B base case. At 10% op margin, earnings power is $3–4/share, implying current valuation fair at best, not cheap.
• ◆Four CEO changes in 18 months permanently damaged organizational execution: strategic whiplash, mid-level attrition, decision delays cost estimated $50–100M in value. Fifth CEO transition risk if Price John cannot establish credibility within 12–18 months weakens competitive position irreversibly.

“Consensus (Hold, $40.67 target, 8 analysts) frames debate as 'Is the tariff pause permanent?' Hold camp prices in continued margin pressure at Vietnam ~20%, limited upside absent tariff clarity + CEO confirmation. Monness Crespi bull argues Q1 FY2026 +10.5% comp recovery proves retail restructuring works operationally; base-case $4+ FY2027 EPS = cheap. Single Sell-rated analyst argues structural impairment (birth rates, OshKosh, retail channel) prices recovery story in entirely. NOT in consensus: $130M IEEPA refund claim (pure upside); governance re-rating potential of Price John hire; FY2027–28 earnings power at normalized gross margins (consensus $3.65 FY2027E vs. our $4.70). Differentiated view: consensus underestimates recovery velocity.”

• ◆Sharon Price John CEO start (June 15, 2026)—strategic continuity communication, first impression on restructuring
• ◆Q2 FY2026 earnings (August 2026)—second consecutive positive comp confirmation, first gross margin read post-Q1, tariff annualization
• ◆Vietnam tariff renegotiation updates (September 2026 deadline)—official policy announcement on 90-day pause extension/revision
• ◆Q3 FY2026 earnings (November 2026)—seasonally highest revenue quarter, comp + margin stabilization confirmation under Price John
• ◆Buyback resumption announcement (FY2027+)—$50M+ program signals management confidence when FCF normalizes to $100M+
• ◆IEEPA refund claim developments—$130M court/administrative decisions provide pure upside optionality
• ◆FY2027 normalized earnings delivery—$4.00–5.00 adj. EPS triggers multiple re-rating
• ◆OshKosh strategic alternatives—sale, divestiture, or restructuring signals capital allocation clarity
• ◆Birth rate trend reversal—any reversal of -1%/year TAM compression structurally benefits long-run thesis

• ◆Vietnam tariff escalation to 46%+ (30% probability): Single largest near-term risk. $100–150M annual COGS headwind invalidates EPS recovery thesis through FY2027. Trigger: Monitor US trade policy announcements, September 2026 deadline. Action: Reduce 50% if tariffs escalate to 35%+, exit if 46%+.
• ◆CEO transition disruption (35% probability): Sharon Price John may revise/pause 150-store closure plan within 90 days. Highest-uncertainty variable with longest feedback loop (12–18 months to verdict). Monitor Q3 FY2026 earnings communication for any guidance revision.
• ◆Q2–Q3 FY2026 comp reversal (25% probability): Q1's +10.5% may be front-loaded pent-up demand; negative comps in Q2–Q3 invalidate retail recovery thesis. Monitor August 2026 earnings, monthly retail indicators.
• ◆Birth rate secular decline (-1%/year, 90% probability ongoing): Slow but irreversible TAM compression; limits long-run earnings ceiling but not a thesis killer in 2–3 year horizon.
• ◆OshKosh brand additional impairment: Non-cash but confirmatory of structural brand erosion; manageable if Carter's core segment remains intact.
• ◆Consumer spending recession (20% probability): Children's apparel near-necessity for 0–24M but more discretionary for 2–12. Moderate impact, delays recovery but not thesis killer.
• ◆FX headwind (International segment, ~40% probability): CAD/MXN depreciation creates $15–25M annual revenue headwind; manageable.
• ◆Mass channel private-label competition intensification: Target Cat & Jack, Amazon private label gaining 2–12 share; Carter's counter-positioning (designs these programs) provides partial protection.